SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,934,262,135 |
| Positions | 57 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Natera Inc | NTRA | COM | $420,823,506 | 1,550,280 |
| Vera Therapeutics Inc | VERA | CL A | $119,889,982 | 2,793,987 |
| Genmab A/S | GMAB | SPONSORED ADS | $111,122,056 | 4,045,215 |
| Jazz Pharmaceuticals PLC | JAZZ | SHS USD | $88,036,221 | 365,341 |
| Rapport Therapeutics Inc | RAPP | COM | $79,356,681 | 1,904,408 |
| Seaport Therapeutics Inc | SPTX | COM | $77,428,998 | 3,564,871 |
| Arrivent BioPharma Inc | AVBP | COM | $58,945,164 | 1,696,752 |
| Ultragenyx Pharmaceutical In | RARE | COM | $57,347,492 | 1,717,505 |
| BioAge Labs Inc | BIOA | COM | $56,220,744 | 2,293,788 |
| Bristol-Myers Squibb Co | BMY | COM | $50,531,011 | 876,970 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.